CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; Carvykti) improved long-term survival among patients with heavily pretreated relapsed/refractory multiple myeloma without any maintenance treatment, according to a post-hoc analysis of the CARTITUDE-1 trial.

Among 97 patients, 45 were still alive and in long-term follow-up, with a median overall survival (OS) of 60.7 months, reported Peter Voorhees, MD, of the Wake Forest University School of Medicine in Charlotte, North Carolina, during a session at the American Society of Clinical Oncology (ASCO) annual meeting.

Moreover, 32 patients were alive and progression-free without any further anti-myeloma treatment 5 or more years after treatment with cilta-cel.

Of these

See Full Page